Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China - PubMed
3 hours ago
- #CDK4/6 inhibitors
- #Real-world evidence
- #Breast cancer treatment
- Abemaciclib combined with endocrine therapy showed a significant progression-free survival (PFS) advantage over palbociclib in Chinese patients with HR-positive/HER2-negative advanced breast cancer.
- In this real-world retrospective study, median PFS was 24 months for palbociclib and 32 months for abemaciclib, while it was not reached for dalpiciclib.
- Abemaciclib benefited various subgroups, including those with endocrine resistance or aggressive disease, with a manageable safety profile, though it had higher rates of low-grade diarrhea compared to more myelosuppression with other inhibitors.